10:27 AM EST, 11/08/2024 (MT Newswires) -- Spectral Medical ( EDTXF ) on Friday reported a wider net loss on higher operating expenses.

Net loss more than doubled to $10 million or $0.04 per share, from $3.8 million or $0.01 per share. The higher loss was due to higher operating expenses, partially offset by a reduced loss from discontinued operations of $130,000.

Revenue increased 26%, to $502,000.

Spectral also reported that 135 patients have been randomized to date out of the target 150 total patients to be enrolled in the Tigris trial. Year-to-date enrollment experienced in 2024 has been robust with 54 patients enrolled so far, the company added.

There are currently 22 Tigris sites operating.

Price: 0.57, Change: -0.02, Percent Change: -3.39